Frank Gerhard

M&A, PTOs, private equity (incl. venture capital), IPOs, equity offerings (incl. innovative structures), shareholder activism, corporate law and governance, securities regulation.

With Homburger since 1998. Foreign Associate at Willkie Farr & Gallagher LLP, New York, 2003-2004. Secondment with Nestlé in 2004. Partner at Homburger since 2005. Authorised representative at SIX Swiss Exchange since 2005.

Admissions: all Swiss courts (1994); New York Bar (1998).

Publications include articles on (i) convergence of private and public markets, (ii) key persons in M&A and superstar-CEOs, (iii) venture capital financing in down rounds, (iv) business judgment rule, (v) reverse stock split, (vi) SPACs and De-SPAC transactions, (vii) equity kickers, (viii) merger of equals and cross-border triangular mergers, (ix) shareholder activism and settlement, (x) banking M&A, (xi) spin-offs and demergers, (xii) company valuations and appraisal rights, (xiii) PIPEs and cornerstone investors and (xiv) private equity financing and exits.

Columbia Law School (LL.M., 1997) University of Neuchâtel (Dr. iur., 2000); Member of the editorial board of the law journal «Gesellschafts- und Kapitalmarktrecht (GesKR)».

• Addex Therapeutics in M&A, corporate and capital markets matters

• Alcon in M&A, corporate, capital markets, stock exchange and financing matters

• Avolta AG (formerly Dufry AG) in M&A, corporate and capital markets matters, recently its strategic combination with Autogrill

• Clariant Ltd in M&A, corporate and capital markets matters, recently in the sale of its worldwide Pigments and Masterbatches businesses, and in the aborted merger of equals with Huntsman

• DKSH Holding AG in M&A, corporate and capital markets matters, recently in the acquisition of Terra Firma and Refarmed

• EQT in the IPO of Galderma and subsequent sell-downs transactions with L’Oréal

• Idorsia in its holistic restructuring

• Temasek in various investments in Switzerland

• Softbank in its investment in GetYourGuide

• Galderma in its IPO on SIX Swiss Exchange

• Various IPOs and rights issues (Dufry, Leonteq, Medacta, PolyPeptide, etc.)